Xtent, Inc., developer of next-generation drug-eluting stent (DES) systems, today announced four-month follow up results from its CUSTOM I trial, designed to demonstrate the Xtent system's ability to customize stent length in situ to accurately match diseased coronary artery lesions. All 30 patients are alive and well, and there was zero percent restenosis.
